Prime leaders appear on PCMA’s podcast on topic “Understanding the value of biosimilars”

Prime’s Dr. Joseph Leach and Jarrod Henshaw discuss the opportunity, how the company’s new MedDrive™ medical drug management product will help manage growing specialty spend

September 8, 2021
Today, spending on biologic drugs makes up 43% of total drug spending. This is a growing area of new innovation for a multitude of therapeutic areas, and also an area of growing cost. To increase the use of biosimilars, strategies must be implemented to focus on biologics and drive cost-savings. To share these strategies, Prime’s Dr. Joseph Leach, senior vice president and chief medical officer and Jarrod Henshaw, senior vice president and Innovation & Supply Chain Officer joined JC Scott, executive director of Pharmaceutical Care Management Association (PCMA) and host of The Pharmacy Benefit podcast. Prime Therapeutics recently announced a major program addressing the increased use of biosimilars. Henshaw explains the differences between traditional drugs vs. biologics and generics drugs vs. biosimilars. Both discuss what it means for biosimilars to be interchangeable, how they confront fears and misperceptions on biosimilars, what roles PBMs must play to drive the cost-savings from adoption of biosimilars, and how policies and incentives can encourage the use of biosimilars.

Listen to the podcast

Explore other previous podcasts by PCMA

Related news

Stories

May 25, 2022

Three Minutes with Kelly Pokuta

Dr. Kelly Pokuta is vice president, trade relations & strategy and chief trade…

Stories

May 23, 2022

Biosimilar use alone won’t cut drug costs

We see it time after time. High-potential innovation that just doesn’t seem to…

Stories

May 13, 2022

Prime expert showcases medical specialty drug management solutions

Prime Therapeutics’ (Prime) Chris Ford, assistant vice president, strategy and innovation, was a…